Skip to Content

KYTH-105 Approval Status

FDA Approved: No
Brand name: KYTH-105
Generic name: setipiprant
Company: Kythera Biopharmaceuticals, Inc.
Treatment for: Androgenetic Alopecia

KYTH-105 (setipiprant) is an oral prostaglandin D2 (PGD2) receptor antagonist in development for the treatment of androgenetic alopecia (AGA), or male pattern hair loss.

Development Status and FDA Approval Process for KYTH-105

DateArticle
Sep 22, 2015Kythera Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide